VIDEO: Studies show immunotherapy 'clearly' benefits some patients with breast cancer
Click Here to Manage Email Alerts
Angela DeMichele, MD, MSCE, co-leader of the Breast Cancer Research Program and director of the Breast Cancer Clinical Trials Unit at Penn Medicine, spoke with Healio about presentations from the 2021 San Antonio Breast Cancer Symposium.
“What we saw at San Antonio this year were further data on the [pembrolizumab] drugs in the early breast cancer setting, through the KEYNOTE-522 [and] KEYNOTE-355 [studies],” DeMichele said.
KEYNOTE-355 compared pembrolizumab plus chemotherapy to placebo plus chemotherapy in patients with previously untreated inoperable or metastatic triple-negative breast cancer.
In KEYNOTE-522, patients with early-stage, high-risk triple-negative disease received pembrolizumab plus chemotherapy or placebo plus chemotherapy in the neoadjuvant setting, followed by pembrolizumab or placebo in the adjuvant setting.
“What we’re seeing is that there are benefits that are clearly there for some patients, that there are survival advantages to patients who get immune therapy. Which patients those are — we have not yet been able to unravel that particular question,” DeMichele said.
References:
Cortes J, et al. GS1-02. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
Schmid P, et al. GS1-01. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-10, 2021; San Antonio.
Collapse
Read more about
Click Here to Manage Email Alerts